SerenQ TB500 10mg Peptide Pen

SerenQ TB500 10 mg contains TB500, a synthetic peptide fragment associated with Thymosin Beta-4 research. Thymosin Beta-4 is a naturally occurring 43-amino-acid protein found throughout human tissue and is studied for its role in cell movement, tissue organisation and repair-related processes.

TB500 represents a shorter active region linked to Thymosin Beta-4 rather than the full protein. Research interest centres on its interaction with actin, an important structural protein that helps cells maintain shape, move and reorganise during tissue repair.

This has made TB500 a common subject in laboratory and animal research looking at cell migration, blood vessel formation, wound repair and connective tissue behaviour.

Pens supplied directly from the manufacturer in sealed retail cartons, with an individual serial number and QR authenticity code for product and batch verification.

Form: Pre-filled pen

• 10 mg of TB500 per pen

• Supplied pre-dissolved in a liquid solution

• 1 dial unit = approximately 50 mcg TB500

• 10 dial units = approximately 500 mcg

• 200 dial units in total across the full pen

• Approximately 20 full 10-unit measurements per pen

• Graduated dial and viewing window for clear unit measurement

• 4 individually sealed 32G 0.23 × 4 mm pen tips supplied

• 4 alcohol swabs supplied

• Protective cap and rigid retail carton included

• Batch number, expiry date and serial number printed directly on the pen

• Individual QR authenticity code for product and batch verification

Handling and storage:

• Store refrigerated at 2–8°C

• Do not freeze

• Keep in the outer carton and protect from direct light

• Short periods at room temperature during transit are expected

• Keep out of reach of children and animals

• Expiry on current sealed stock: 12/2027

What is in the box:

• 1 × SerenQ TB500 10 mg pre-filled pen

• 4 × sealed 32G pen tips

• 4 × alcohol swabs

• 1 × serialised, QR-coded retail carton

TB500 is supported primarily by animal and laboratory research. The synthetic fragment itself is not a licensed medicine and has no approved clinical indication. SerenQ TB500 is supplied as a research-grade material rather than an approved treatment.